Compare Humana Inc (HUM) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Teradyne, Inc. — how do they compare? Humana Inc trades at $406.88 (market cap $47.81B), while Teradyne, Inc. trades at $374.74 (market cap $52.25B). The key difference: Humana Inc and Teradyne, Inc. are close in size by market cap, and Humana Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| HUM | TER | |
|---|---|---|
Market Cap | $47.81B | $52.25B |
Sector | Health | Technology |
52-Week High | $409.42 | $483.84 |
52-Week Low | $163.67 | $90.15 |
Enterprise Value | $56.85B | $52.08B |
Dividend Yield | 0.89% | 0.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $398.09, down 0.48% with a bullish technical signal from moving averages. The company shows strong revenue growth to $129.66B in 2025 but faces margin compression with net income margin declining to 0.82%. Recent earnings have consistently beaten expectations, and analyst sentiment is mixed with 34% buy ratings but a consensus price target of $354.33 below current levels.
The outlook suggests cautious optimism with Medicare Advantage expansion opportunities but significant margin pressure and regulatory risks. Key investment considerations include the company's ability to achieve its 3% Medicare Advantage margin target by 2028 while navigating increased healthcare utilization costs and competitive pressures in the insurance sector.
Teradyne (TER) trades at $334.23, up 3.68% on the day, with strong recent earnings beats and robust AI-driven semiconductor testing demand. The stock shows bearish technical signals but benefits from high profitability margins (net income margin 22.55%) and consistent revenue growth, projected to reach $3.8B in 2026. Analysts maintain a bullish consensus with a $453.60 price target, citing AI infrastructure expansion and recent product launches as key catalysts.
Outlook remains positive given TER's strategic positioning in AI and semiconductor testing, though elevated valuation ratios (P/E 59.81) and technical bearishness pose near-term risks. Investment opportunity hinges on execution in high-growth AI segments, while risks include market volatility and competitive pressures in the chip equipment sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
